MediWound (MDWD) Non Operating Interest Expenses (2013 - 2026)
MediWound (MDWD) posted Non Operating Interest Expenses of -$1.1 million for Q2 2026, up 54.52% on a QoQ basis from -$2.5 million in Q4 2025, and up 85.98% year-over-year from -$602768.4 in Q2 2025.
Analysis
MediWound (MDWD) Non Operating Interest Expenses (2013 - 2026) Analysis & Trends
MediWound has reported Non Operating Interest Expenses for 14 years, with the latest figure at -$1.1 million in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 85.98% year-over-year to -$1.1 million in Q2 2026; TTM through Jun 2026 was -$7.6 million, a 32.75% increase from a year earlier, with the FY2025 full-year figure at -$2.5 million, up 80.79% from the prior year.
- Non Operating Interest Expenses was -$1.1 million for Q2 2026 at MediWound, up from -$2.5 million in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $4.0 million in Q3 2025, with the low at -$8.0 million in Q2 2025.
- Average Non Operating Interest Expenses over 5 years is -$1.1 million, with a median of -$781000.0 recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: Non Operating Interest Expenses soared 159.06% in 2022, then slumped 232.35% in 2025.
- Over 5 years, Non Operating Interest Expenses stood at $375000.0 in 2022, then slumped by 338.13% to -$893000.0 in 2023, then slumped by 169.32% to -$2.4 million in 2024, then decreased by 2.49% to -$2.5 million in 2025, then surged by 54.52% to -$1.1 million in 2026.
- The last three Non Operating Interest Expenses figures came in at -$1.1 million (Q2 2026), -$2.5 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | MediWound | 156.09 Mn | 120.75 Mn | 337,000.00 | -1.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.12 Mn |
| Dec 31, 2025 | -2.47 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | -7.99 Mn |
| Mar 31, 2025 | 4,000.00 |
| Jun 30, 2024 | -2.41 Mn |
| Jun 30, 2023 | -893,000.00 |
| Dec 31, 2022 | 375,000.00 |
| Sep 30, 2022 | -781,000.00 |
| Jun 30, 2022 | -687,000.00 |
| Mar 31, 2022 | -440,000.00 |
| Dec 31, 2021 | -635,000.00 |
| Sep 30, 2021 | -457,000.00 |
| Jun 30, 2021 | -399,000.00 |
| Mar 31, 2021 | -941,000.00 |
| Dec 31, 2020 | 657,000.00 |
| Sep 30, 2020 | -541,000.00 |
| Jun 30, 2020 | -491,000.00 |
| Mar 31, 2020 | -494,000.00 |
| Dec 31, 2019 | -382,000.00 |